Kliniken & Institute ... SFBs SFB TRR156 Research Research Area B: Immune...

B07: Effects of antipsoriatic therapies on aberrant IL-6/STAT3 signaling in psoriasis

Universitäts-Hautklinik Tübingen

Psoriasis is a Th17-mediated skin inflammation with aberrant keratinocyte cell signaling, genetic and epigenetic alterations. Interestingly, psoriasis responds to very distinct treatments like anthralin, PUVA phototherapy, anti-TNF or anti-p40. In contrast to therapies neutralizing cytokines, anthralin and PUVA both even induce inflammatory mediators like IL-6 and ROS. By studying human and murine keratinocytes and immune cells in Th17-skin inflammation we want to identify the therapy-induced cytokine- and ROS-dependent molecular events on these cell types and the resulting IL-23/Th17 response. The CRC allows us an improved understanding of the crosstalk between these cell types.

Quelle: Universitäts-Hautklinik Tübingen

Principal investigators

Dr. med. Franziska Carola Eberle

Universitäts-Hautklinik Tübingen

PD Dr. med. Kamran Ghoreschi

Universitäts-Hautklinik Tübingen